Janssen to present new oncology data at ASH 2013

Janssen has announced it will be sharing information on its latest oncology advances at the forthcoming American Society of Hematology (ASH) annual meeting.

Taking place in New Orleans from December 7th to 10th 2013, the event will provide Janssen with an opportunity to present nine pieces of company-sponsored research, spanning a total of nearly 50 abstracts.

Presentations will cover investigational uses of the US-approved compound ibrutinib, new findings on the promising multicentric Castleman disease therapy siltuximab and additional data for the multiple myeloma treatment daratumumab.

Much of this data has been or is being used to support recent or ongoing regulatory assessments for these treatments.

Dr Peter Lebowitz, global oncology therapeutic area head at Janssen, said: "Therapies for haematologic malignancies are the cornerstone of our broad oncology portfolio at Janssen Research and Development."

This comes after the company attended the latest meetings of the American Association for the Study of Liver Diseases and International Society of Pharmacoeconomics and Outcomes Research earlier this month, where it shared data on its hepatitis C therapy Incivo.